

DAFTAR PUSTAKA

- Abdel-Misih, S.R.Z., Bloomston, M. 2010. Liver Anatomy. *Surgical Clinics of North America*. 90 (2010) 643–653. doi:10.1016/j.suc.2010.04.017
- Adaninggar, P.N., Kholili, U., Maimunah, U., Setiawan, P.B., Nusi, I.A., Purbayu, H., *et al.* 2016. Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*. Volume 17, Number 1, April 2016.
- Alianto, R. 2015. Gambaran Histopatologi Karsinoma Hepatoseluler. *Cermin Dunia Kedokteran*. 229/ vol. 42 no. 6, th. 2015. Pp440-4.
- Arslanoglu, A., Seyal, A.R., Sodagari, F., Sahin, A., Miller, F.H., Salem, R., Yaghmai, V. 2016. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. *American Journal of Roentgenology*. 2016; 207:W1–W11. DOI:10.2214/AJR.15.15490
- Bağirsakç1, E., Şahin, E., Atabey, N., Erdala, E., Guerra, V., Carr, B.I. 2017. Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. *Oncology*. DOI: 10.1159/000471807
- Bernardi, M., Maggioli, C., Zaccherini, G. 2012. Human albumin in the management of complications of liver cirrhosis. *Critical Care*. 2012, 16:211. DOI: 10.1007/978-3-642-25716-2
- Carr, B.I., Guerra, V. 2017. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. *International Journal of Biological Markers*. 2017; 32(4): e391-e396. DOI: 10.5301/ijbm.5000300
- Carr, B.I., Guerra, V. Giannini, E.G., Farinati, F., Ciccarese, F., Rapaccini, G.L., *et al.* 2014a. Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. *Seminars in Oncology*, Vol 41, No 2, April 2014, pp 252-258. <http://dx.doi.org/10.1053/j.seminoncol.2014.03.006>
- Carr, B.I., Guerra, V. Giannini, E.G., Farinati, F., Ciccarese, F., Rapaccini, G.L., *et al.* 2014b. Significance of platelet and AFP levels and liver function parameter for HCC size and survival. *International Journal of Biological Markers*. 2014,29 (3): e215-e223. DOI: 10.5301/jbm.5000064.
- Cartier V., Aubé, C. 2014. Diagnosis of hepatocellular carcinoma. *Diagnostic and Interventional Imaging*. <http://dx.doi.org/10.1016/j.diii.2014.06.004>
- Chang, K.B., Chi, C.T., Lee, R.C., Hou, M.C., Huang, Y.H., Lee, I.C. 2021. Efficacy and predictors of survival in patients with solitary hepatocellular carcinoma larger than 5 cm undergoing transarterial chemoembolization. *Advances in Digestive Medicine*. 2021; 1-9. DOI : 10.1002/aid2.13278.
- Cheng, A.L., Amarapurkar, D., Chao, Y., Chen, P., Geschwind, J., Goh, K.L., *et al.* 2014. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. *Liver International*. 2014: 34: 174–183. DOI:10.1111/li.v.12314
- Choi, J.Y., Lee, J.M., Sirin, C.B. 2014a. CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and

- Spread: Key Pathologic and Imaging Aspects. *Radiology*. 2014; 272:635–654. DOI : 10.1148/radiol.14132361
- Choi, J.Y., Lee, J.M., Sirlin, C.B. 2014b. CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma. Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. *Radiology*. 2014; 273:30–50. DOI: 10.1148/radiol.14132362
- Cunha G.M., Chernyak, V., Fowler, K.J., Sirlin, C.B. 2021. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*. 2021;8:513-527. <https://doi.org/10.2147/JHC.S268288>
- Ellis, H. 2011. Anatomy of the liver. *Surgery* : 29(12), pp. 589– 592. *Elsevier Ltd*. doi: 10.1016/j.mpsur.2011.09.012.
- Fateen, W., Ryder, R.D. 2017. Screening for hepatocellular carcinoma: patient selection and perspectives. *Journal of Hepatocellular Carcinoma*. 2017;4 71–79. <http://dx.doi.org/10.2147/JHC.S105777>
- Forner, A., Reig, M., Bruix, J. 2018. Hepatocellular carcinoma. *Lancet*. 2018; 391: 1301–14. [http://dx.doi.org/10.1016/S0140-6736\(18\)30010-2](http://dx.doi.org/10.1016/S0140-6736(18)30010-2)
- Fourniera, L., Ammaria, S., Thiama, R., Cuénoda, C.A. 2014. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. *Diagnostic and Interventional Imaging*. 2014 : 95, 689—703. <http://dx.doi.org/10.1016/j.diii.2014.05.002>
- Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J.L., *et al*. 2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*. 2018 : vol. 69 j 182–236
- Georgiades, C., Geschwind, J.F., Harrison, N., Hines-Peralta, A., Liapi, E., Hong, K., *et al*. 2012. Lack of response after initial chemoembolization for hepatocellular carcinoma: Does It Predict Failure of Subsequent Treatment?. *Radiology*. 2012; 265:115–123. DOI:10.1148/radiol.12112264
- Goh, G.B., Li, J.W., Chang, P.E., Chow, K.Y., Tan, C.K. 2017. Deciphering the Epidemiology of Hepatocellular Carcinoma Through the Passage of Time: A Study of 1,401 Patients Across 3 Decades. *Hepatology Communications*. 2017;1:564–571. DOI :10.1002/hep4.1059
- Golfieri, R., Cappelli, A., Cucchetti, A., Piscaglia, F., Carpenzano, M., Peri, E., *et al*. 2011. Efficacy of Selective Transarterial Chemoembolization in Inducing Tumor Necrosis in Small (< 5 cm) Hepatocellular Carcinomas. *Hepatology*. Vol. 53, No. 5, 2011. DOI :10.1002/hep.24246
- Gonzalez-Guindalini, F.D., Botelho, M.P.F., Harmath, C.B., Sandrasegaran, K., Miller, F.H., Salem, R., *et al*. 2013. Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. *RadioGraphics*. 2013; 33:1781–1800. DOI : 10.1148/rg.336135511
- Goto, K., Suarez, A.A.R., Wensch, F., Baumert, T.F., Lupberger, J. 2020. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. *International Journal of Molecular Science*. 2020, 21, 3057; DOI:10.3390/ijms21093057
- Guerrieri, F., Belloni, L., Pediconi, N., Levrero, M. 2013. Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. Article in *Seminars in Liver Disease* · May 2013. DOI: 10.1055/s-0033-1345721
- Hamid, A.S., Tesfamariam, I.G., Zhang, Y., Zhang, Z.G. 2013. Afltoxin B1-induced hepatocellular carcinoma in developing countries: Geographical

- distribution, mechanism of action and prevention (Review). *Oncology Letters* 5: 1087-1092, 2013. DOI: 10.3892/ol.2013.1169.
- Han, G., Berhane, S., Toyoda, H., Bettinger, D., Elshaarawy, O., Chan, A.W.H., *et al.* 2020. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. *Hepatology*. Vol. 0, No. 0, 2020. DOI 10.1002/hep.31022
- Han, K., Kim, J.H. 2015. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. *World Journal of Gastroenterology*. 2015 September 28; 21(36): 10327-10335. DOI: 10.3748/wjg.v21.i36.10327
- Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, *et al.* 2016. Usefulness of albumin-bilirubin (ALBI) *grade* for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. DOI: 10.1111/JGH_13250.AA
- Ho, S.Y., Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Lee, R.C., *et al.* 2017. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS ONE*. 12(7): e0180408. <https://doi.org/10.1371/journal.pone.0180408>.
- Hoekstra, L.T., de Graaf, W., Nibourg, G.A.A., Heger, M., Bennink, R.J., Stiegre, B., *et al.* 2013. Physiological and Biochemical Basis of Clinical Liver Function Tests. *Annals of Surgery*. 2013;257: 27–36. DOI: 10.1097/SLA.0b013e31825d5d47
- Husodo, U. B. 2014. Kanker hati. In S. S. Ari W Sudoyo, Bambang Setiyohadi, Idrus Alwi (Ed.), *Buku Ajar ilmu Penyakit Dalam*. jilid I edisi VI., jakarta: Interna Publishing, pp. 3030–36
- Hyun, D., Shin, S.W., Cho, S.K., Park, K.B., Park, H.S., Choo, S.W., *et al.* 2014. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta Radiologica*. 0(0) 1–9. DOI: 10.1177/0284185114560937
- Idée, J.M., Guiu, B. 2013. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. *Critical Reviews in Oncology/Hematology*. 88 (2013) 530–549. <http://dx.doi.org/10.1016/j.critrevonc.2013.07.003>
- Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., *et al.* 2014. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI *Grade*. *Journal Clinical of Oncology*. 33:550-558. DOI: 10.1200/JCO.2014.57.9151
- Khalid, M.A., Achakzai, I.K., Hanif, F.M., Ahmed, S., Majid, Z., Luck, N.H. 2019. To determine the prognostic value of the albumin–bilirubin *grade* (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. *Gastroenterology and Hepatology From Bed to Bench*. 2019;12(2):110-115.
- Kohla, M.A.S., Zeid, M.I.A., Al-Warraky, M., Taha, H., Gish, R.G. 2015. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. *BMJ Open Gastroenterology*. 2015; 2:e000032. doi:10.1136/bmjgast-2015-000032

- Kulik, L., El-Serag, H.B. 2019. Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*. 2019;-:1 –15.
- Kwan, S.W., Fidelman, N., Ma, E., Kerlan, Jr. R.K., Yao, F.Y. 2012. Imaging Predictors of the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Radiological Pathological Correlation. *Liver Transplantation*. 18:727-736, 2012. DOI 10.1002/lt .23413
- Le, Y., Shen, J.X., Zhang, Y.F., He, M.K., Kan, A., Chen, H.L., *et al.* 2019. Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. *Journal of Cancer*. 2019; 10(3): 665-671. doi: 10.7150/jca.28528
- Lencioni, R. 2013. New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma. *Clinical Cancer Research*. 19(6) March 15, 2013. DOI: 10.1158/1078-0432.CCR-12-3796
- Llovet, J.M., Lencioni, R. 2020. mRECIST for HCC: Performance and novel refinements. *Journal of Hepatology*. 2020 vol. 72 j 288–306
- Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., *et al.* 2021. *Hepatocellular carcinoma*. <https://doi.org/10.1038/s41572-020-00240-3>
- Lo, C.M., Ngan, H., Tso, W.K., Liu, C.L., Lam, C.M., Poon, R.T-P., *et al.* 2002. Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma. *Hepatology*, Vol. 35, No. 5, 2002. doi:10.1053/jhep.2002.33156.
- Loffroy, R., Estivalet, L., Favelier, S., Pottecher, P., Genson, P.Y., Cercueil, J.P., *et al.* 2015. Interventional radiology therapies for liver cancer. *Hepatoma Research*. 2016;2:1-9. DOI: 10.4103/2394-5079.167439
- Maida, M., Cabibbo, G., Brancatelli, G., Genco, C., Alessi, N., Genova, C., *et al.* 2013. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. *Future Oncology*. (2013) 9(6), 845–854.
- Marrero, J.A., Kulik, L.M., Sirlin, C., Zhu, A.X., Finn, R.S., Abecassis, M.M., *et al.* 2018. Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* for publication on March 12, 2018 . doi: 10.1002/hep.29913
- Mendez-Sanchez, N., Qi, X., Vitek, L., Arrese, M. 2019. Evaluating an Outpatient With an Elevated Bilirubin. *American Journal of Gastroenterology*. 2019;114: 1185– 1188. <https://doi.org/10.14309/ajg.0000000000000036>
- Nishino, M., Jagannathan, J.P., Ramaiya, N.H., den Abbeele, A.D. 2011. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. *American Journal of Roentgenology*. 195(August 2010), pp. 281 –289. doi:10.2214/AJR.09.4110
- Pabst, R., 2011. Anatomy Atlas of Human Edited Volume 2 Lower Limb Trunk , Viscera., 15th ed. Elsevier Ltd, Munich.
- Peng, Y.F., Goyal, H., Xu, G.D. 2017. Serum bilirubin has an important role in multiple clinical applications. *Journal of Laboratory and Precision Medicine*. 2017;2:82. <http://dx.doi.org/10.21037/jlpm.2017.09.08>
- Piscaglia, Fabio., Ogasawara, S. 2018. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of

- Benefit/Risk Assessment. *Liver Cancer*. 2018;7:104–119. DOI: 10.1159/000485471
- Poedjomartono, B., Faisal, A., Nurjanah, S. 2020. Transarterial Chemoembolization in Hepatocellular Carcinoma: A Clinical Efficacy Study of Ganoderma Lucidum Extract Polysaccharide Peptide β -Glucan. *Bali Medical Journal* 9(1): 31-35. DOI:10.15562/bmj.v9i1.1610
- Prajapati, H.J., Spivey, J.R., Hanish, S.I., El-Rayes, B.F., Kauh, J.S., Chen, Z., *et al.* 2013. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). *Annals of oncology : official journal of the European Society for Medical Oncology*. 24(4), 965–973. <https://doi.org/10.1093/annonc/mds605>
- Rabouhans, J. S., Baron, A., Cazejust, J., Rosmorduc, O., Menu, Y. 2011. A radiologist's guide to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessment of therapy for hepatocellular carcinoma', European Society of Radiology. Electronic Presentation Online System, Poster C-2, pp. 1–42. doi: 10.1594/ecr2011/C-2120.
- Reeves, H.L., Zaki, M.Y.W., Day, C.P. 2016. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. *Digestive Diseases and Science*. (2016) 61:1234–1245. DOI 10.1 007/s10620-016-4085-6
- Santillan, C. 2020. CT and MRI of the liver for hepatocellular carcinoma. *Hepatoma Research*. 2020;6:63. <http://dx.doi.org/10.20517/23945079.2020.60>
- Sastroasmoro, S., Ismael, S. 2011. Usulan Penelitian. *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, pp. 31 –63.
- Sato, Y., Watanabe, H., Sone, M., Onaya, H., Sakamoto, N., Osuga, K., *et al.* 2013. Tumor response evaluation criteria for HCC treated using TACE: RECIST version 1.1 and mRECIST. *Upsala Journal of Medical Sciences*. 2013; 118: 16–22 . DOI: 10.3109/03009734.2012.729104
- Shim, J.H., Lee, H.C., Kim, S.O., Shin, Y.M., Kim, K.M., Lim, Y.S., *et al.* 2012. Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization ?. A Validation Study of Old and New Models. *Radiology*. 2012; 262:708–718. DOI : 10.1148/radiol.11110282
- Sibulesky, L. 2013. Normal Liver Anatomy. *Clinical Liver Disease*. Vol 2, No. S1, March 2013. Doi : 10.1..2/cld.124.
- Sieghart, W., Huckle, F., Radosavljevic, M.P. 2015. Transarterial chemoembolization : Modalities, indication, and patient selection. *Journal of Hepatology*. 2015 vol. 62 j 1187–1195.
- Siregar, G.A. 2011. Penatalaksanaan non bedah dari karsinoma hati. *Universa Medicina*. Vol.24 No.1. pp35-42.
- Su, T.S., Yang, M.H., Zhou, Y., Huang, Y., Liang, P., Cheng, T., *et al.* 2019. Albumin - bilirubin (ALBI) versus Child Turcotte Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. *Radiation Oncology*. (2019) 14:50. <https://doi.org/10.1186/s13014-019-1251-y>
- Taniai, M. 2020. Alcohol and hepatocarcinogenesis. *Clinical and Molecular Hepatology*. 2020;26:736-741. <https://doi.org/10.3350/cmh.2020.0203>.

- Tarocchi, M., Polvani, S., Marroncini, G., Galli, A. 2014. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. *World Journal of Gastroenterology*. 2014 September 7; 20(33): 11630-11640
- Trefts, E., Gannon, M., Wasserman, D.H. 2017. The Liver. *Current Biology*. 2017 November 06; 27(21): R1147–R1151. doi:10.1016/j.cub.2017.09.019.
- Varzaneh, F.N., Pandey, A., Ghasabeh, M.A., Shao, N., Khoshpouri, P., Pandey, P., *et al.* 2018. Prediction of post-TACE necrosis of hepatocellular carcinoma using volumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. *European Radiology*. 2018 July ; 28(7): 3032–3040. doi:10.1007/s00330-017-5198-9.
- Villanueva, A. 2019. Hepatocellular Carcinoma. *The New England Journal of Medicine*. 2019;380:1450-62. DOI: 10.1056/NEJMra1713263
- Wardani, P.W., Poedjomartono, B., Gunarti, H. 2020. Hubungan Antara Karakteristik Morfologi Pencitraan Tumor Karsinoma Hepatoseluler pada CT Scan Abdomen Kontras 4 Fase dengan Respon Terapi *Transarterial Chemoembolization*. *Tesis*. Universitas Gadjah Mada, Yogyakarta.
- White, J.A., Redden, D.T., Bryant, M.K., Dorn, D., Saddekni, S., Aal, A.K.A., *et al.* 2014. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. *International Hepato-Pancreato-Biliary Association*. DOI:10.1111/hpb.12313
- Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A., Roberts, L.R. 2019. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nature reviews. Gastroenterology & Hepatology*. <https://doi.org/10.1038/s41575-019-0186-y>
- Yi, S.W., Choi, J-S., Yi, J.J., Lee, Y.H., Han, K.J. 2018. Risk Factors for Hepatocellular Carcinoma by Age, Sex , and Liver Disorder Status : A Prospective Cohort Study in Korea. *Cancer*. July 1, 2018. DOI:10.1002/cncr.31406.
- Zheng, B., Zhu, Y.J., Wang, H.Y., Chen, L. 2017. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. *Science China Life Sciences*. doi: 10.1007/s11427-016-9043-9
- Zhu, R. X., Seto, W., Lai, C., Yuen, M. 2016. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut and Liver*. Vol. 10, No. 3, May 2016, pp. 332-339. <http://dx.doi.org/10.5009/gnl15257>